# Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer

> **NCT05446324** · PHASE3 · UNKNOWN · sponsor: **UMC Utrecht** · enrollment: 10 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Gallium-68-tilmanocept

## Key facts

- **NCT ID:** NCT05446324
- **Lead sponsor:** UMC Utrecht
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-15
- **Primary completion:** 2024-07-01
- **Final completion:** 2024-09-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05446324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05446324, "Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05446324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*